DFDA

Cisplatin-based Chemotherapy

Treatment for Hepatoblastoma

Typical Dosage: Various regimens, e.g., Cisplatin 80-100 mg/m2 per cycle

Effectiveness
85%
Safety Score
25%
Clinical Trials
1
Participants
15K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Various regimens, e.g., Cisplatin 80-100 mg/m2 per cycle
Time to Effect
2-4 weeks
Treatment Duration
4-6 months
Evidence Quality
HIGH
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,000
Monitoring:$40,000
Side Effect Mgmt:$50,000
Total Annual:$95,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
QALYs Gained
18
Outcome-Based Costs
Cost per Responder
$135,714.28
Cost per Remission
$135,714.28
Cisplatin-based Chemotherapy Outcomes

for Hepatoblastoma

Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+70%
Remission Rate
+70%
Common Side Effects
Nausea and vomiting
+85%
Myelosuppression
+80%
Ototoxicity
+40%
Nephrotoxicity
+35%
Fatigue
+80%

Sources:

droracle.ai
nih.gov
researchgate.net

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
1 active trial recruiting for Cisplatin-based Chemotherapy in Hepatoblastoma

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

NCT00980460ACTIVE NOT RECRUITINGPHASE3
View Study
236 participants
INTERVENTIONAL
Birmingham, United States +208 more
Started: Sep 14, 2009